They saw some positive results in Cohort 3 on fewer treatments so probably thought they could see positive ones in the FX trial and it would help stock and to raise capital to fund CX and possibly other trials, and also maybe provide more partnership opportunities.
It total backfired as we know. The blood data will probably be out in early 2017, that is the next real catalyst unless we see anything on the Melanoma studies.
News 
Market Data 
Discover 
